CURRENT POLICY ON HEPATITIS B VACCINATION AMONG TERTIARY CARE HOSPITAL HEMODIALYSIS PATIENTS

RA KHAN; ZA KHAN; M SHAHZAD; A GHANI; L ALI

doi:10.54112/bcsrj.v2024i1.658

Authors

RA KHAN Department of Nephrology, Miangul Abdul Haq Jahanzeb Kidney Hospital Swat, Pakistan
ZA KHAN Department of Urology, MMC Mardan, Pakistan
M SHAHZAD Department of Urology, Institute of Kidney Disease, Peshawar, KPK, Pakistan
A GHANI Department of Urology, MTI- Lady Reading Hospital, Peshawar, KPK, Pakistan.
L ALI Department of Urology, Institute of Kidney Disease, Peshawar, KPK, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.658

Keywords:

Hemodialysis, HBV Immunization, And Chronic Kidney Disease

Abstract

A study was conducted at the Miangul Abdul Haq Jahanzeb Kidney Hospital in Swat to evaluate the vaccination status for hepatitis B among hemodialysis patients with chronic renal disease. The focus of the study was to determine the effectiveness of the hepatitis B vaccine in generating anti-HBS antibodies in this specific patient population. The primary objective was to identify and assess the hepatitis B vaccination status in patients undergoing hemodialysis due to chronic renal disease. This study aimed to determine the presence of anti-HBS antibodies in the patient's blood after receiving three or four doses of the 20-microgram hepatitis B vaccine between January 2022 and January 2023. The study followed a cross-sectional. The participants included hemodialysis patients with chronic renal disease. The validation of hepatitis B vaccination status was based on the measurement of the anti-HBS antibody titer in the patients' blood. This measurement was taken after administering three or four doses of the 20-microgram hepatitis B vaccine. A cut-off anti-HBS antibody titer of ≥10 IU/L was used to determine the effectiveness of the vaccination. The study included a total of 55 registered patients in the age range of 25 to 65 years. The average age of the patients was 48.70 ± 5.245 years. Among the participants, there was a ratio of 1.6:1, with 28 (25.7%) patients receiving three doses of the hepatitis B vaccination and 81 (72.2%) patients receiving four doses. The results indicated that 40 patients (50.2%) had confirmed vaccinations, as evidenced by an anti-HBS antibody titer of ≥10 IU/L. Patients with chronic kidney disease had a lower chance of developing anti-HBS antibodies with ≥ ten IU/L after hepatitis immunization. Individuals who get vaccinations early in the disease have a higher chance of developing advanced immunity.

Downloads

Download data is not yet available.

References

Ahmed, M. M. M., Hassan, H. E., Mohamed, A. A. E., and Saleh, A. S. E. M. (2024). Knowledge and Practice of Nurses toward Preventive Measures of Elderly Patients with Viral Hepatitis B and C in the Dialysis Unit. NILES journal for Geriatric and Gerontology 7, 70-91.

El-Sokkary, R. H., Tash, R. M. E., Mortada, E. M., and El Seifi, O. S. (2020). Evaluation of a hepatitis B virus protection intervention among interns at Zagazig University Hospitals, Egypt. Infection, Disease & Health 25, 50-59.

Hettenbaugh, J., Mullane, R., Gillispie, G., Shostrom, V., Flores, L., Fillaus, J. A., Florescu, M. C., Murcek, D., and Tendulkar, K. K. (2021). Hepatitis B Vaccination in Advanced Chronic Kidney Disease: A Quality Improvement Project at a Veteran Affairs Chronic Kidney Disease Clinic. Infectious Disease Reports 13, 1036-1042.

Hussein, M., El-Raouf, A., and EmadEldien, M. (2021). Prevalence of Hepatitis B and CViruses among Health Care Workers at Governmental Hemodialysis Units. Mansoura Nursing Journal 8, 183-202.

Mahupe, P., Molefe-Baikai, O., Saleshando, G., and Rwegerera, G. (2021). Prevalence and risk factors for hepatitis b and c among end-stage renal disease patients on hemodialysis in Gaborone, Botswana. Nigerian Journal of Clinical Practice 24, 81-88.

Mtingi-Nkonzombi, L., Manning, K., Ensor, J., Surdut, S., Gigi, N., Walton, N., and Freercks, R. (2022). Prevalence of hepatitis B and vaccination response in patients with end-stage kidney disease on dialysis at a tertiary centre in the Eastern Cape province of South Africa. African Journal of Nephrology 25, 101-107.

Nadeem, M., Shah, S. A. A., Arshad, N., Riaz, F., Kiani, R. S., and Quddus, M. A. (2021). Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan. F1000Research 10, 55.

Okoye, O. C. (2020). Sero-prevalence of Hepatitis B and C infection among patients with end stage renal disease at haemodialysis initiation. African Journal of Medical and Health Sciences 19, 1-6.

Orji, C. J., Chime, O. H., and Ndibuagu, E. O. (2020). Vaccination status and prevalence of hepatitis B virus infection among health-care workers in a tertiary health institution, Enugu State, Nigeria. Proceedings of Singapore healthcare 29, 119-125.

Patnaik, S. K., Sahu, M. K., Sahu, T., Uthansingh, K., and Mohanty, S. (2021). Adherence to multidose Hepatitis B vaccination in a Tertiary Care Centre: A Retrospective Cohort Study. Indian Journal of Public Health Research & Development 12.

Raina, D., Rawat, N., and Pandita, A. K. (2022). Prevalence of Hepatitis B and Hepatitis C in Patients undergoing hemodialysis at a teaching hospital in Uttarakhand. Journal of family medicine and primary care 11, 1348.

Saeed, L., Al-Jelaify, M., Alkhani, N., Moammar, T. B., Binkhamis, K., and Alfurayah, R. (2023). Seroprevalence of hepatitis B virus infection among healthcare workers in an academic tertiary care center, Riyadh, Saudi Arabia: A cross-sectional study. Saudi Journal of Clinical Pharmacy 2, 115-119.

Shrestha, S., Tiwari, P. S., and Pradhan, B. (2021). Occult hepatitis B infection in end-stage renal disease patients starting maintenance hemodialysis at a tertiary care hospital: a descriptive cross-sectional study. JNMA: Journal of the Nepal Medical Association 59, 336.

Vinayakumar, A. N., and John, R. (2020). Seroprevalence of hepatitis C infection in patients undergoing haemodialysis in a tertiary care centre. Journal of Patient Safety and Infection Control 8, 48-53.